Alexion (ALXN) and Celgene (CELG) Ratings Discusses as Revlimid Maintenance Has Last Showing Before Approval
In a Piper Jaffray research report this morning Alexion (NasdaqGS: ALXN) and Celgene (NasdaqGS: CELG) are both reviewed as they are awaiting approval for Soliris and Revlimid Maintenance respectively.
Alexion has an Overweight rating with a price target of $86.
Alexion closed Monday at $72.73.
Celgene has an Overweight rating with a price target of $81.
Celgene closed Monday at $60.96.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted-In: Alexion Celgene Piper JaffrayAnalyst Color Price Target Analyst Ratings